Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15709)	2/23/1998 2:27:00 PM
From: Flagrante Delictu	Read Replies (4) \| Respond to of 32384

Henry, I have noticed that a number of our posters are concerned that the breast cancer studies with Targretin were conducted on rodents instead of larger mammals. This led me to wonder whether, when you were a young unmarried biochemist in Chicago, you ever conducted experiments using bunnies. Bernie P.S. I realize that you may be too busy to answer this one.

To: Henry Niman who wrote (15709)	2/23/1998 2:37:00 PM
From: Machaon	Read Replies (2) \| Respond to of 32384

<< Ligand has 200 issued patents >> The FDA couldn't possibly know all of the complexities when it comes to the science behind all of the new drugs, especially those that are breaking new scientific ground. Let's assume, for discussion sake, that the science behind Sparta's Retinoid patent overlaps some of Ligand's patents (I assume that this happens occasionally). Does the one holding the first patent win the patent rights, or does it get more complex than that? In other words, using your comparison between Ligand's many Retinoid patents, and Sparta's one patent: How comfortable can Sparta be about their patent being upheld in the future? Thanks, Bob